VALERIA SANTINI

ASSOCIATE PROFESSOR

University of Florence

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Valeria Santini is an Associate Professor at the University of Florence, Italy. Her research primarily focuses on myelodysplastic syndromes, including recent studies on treatment options such as luspatercept and erythropoiesis-stimulating agents. She has contributed to the understanding of genetic factors and therapeutic strategies in hematologic malignancies, particularly acute leukemias and chronic myelomonocytic leukemia.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (8)

María Díez Campelo

Universidad de Salamanca

SPAIN

View details

sylvain thepot

Université d'Angers

FRANCE

View details

Agnieszka Wierzbowska

Medical University of Lodz

POLAND

View details

Michele Ceccarelli

University of Miami

UNITED STATES

View details

Nathalie Droin

Inserm u1183

FRANCE

View details

Aristoteles Giagounidis

Head of department

Katholisches Klinikum Koblenz

GERMANY

View details

lionel adès

Professor

FRANCE

View details

Yan Guo

University of Miami

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

VALERIA SANTINI

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Genome-Wide Methylome Modeling via Generative AI Incorporating Long- and Short-Range Interactions

How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome

New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes

TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia

Treatment of Lower Risk Myelodysplastic Syndromes

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels

Collaborators (8)

María Díez Campelo

sylvain thepot

Agnieszka Wierzbowska

Michele Ceccarelli

Nathalie Droin

Aristoteles Giagounidis

lionel adès

Yan Guo

Make your next move.